VOLUME 9 (2018)
View Archive »
About The Cover
The cover for issue 70 of Oncotarget features Figure 4B, "BRAF/MEK inhibitor-based phase 1 trial therapy according to BRAF or KRAS hotspot mutation status," by Wang, et al.
Table of Contents
News
|
| Drug repurposing using highthroughput screening identifies a promising drug combination to treat adrenocortical carcinoma |
|
https://doi.org/10.18632/oncotarget.26091
|
| 33245-33246 |
Editorial
|
| The role of p16 as a biomarker in nonoropharyngeal head and neck cancer |
|
https://doi.org/10.18632/oncotarget.26053
|
| 33247-33248 |
Priority Research Papers
|
| Modeling and antitumor studies of a modified L–penetratin peptide targeting E2F in lung cancer and prostate cancer |
|
https://doi.org/10.18632/oncotarget.26064
|
| 33249-33257 |
Research Papers
|
| Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.25947
|
| 33258-33270 |
|
| Glioblastoma in the setting of prior lower grade gliomas – insights from SEER database |
|
https://doi.org/10.18632/oncotarget.26014
|
| 33271-33277 |
|
| Metabolite quantification of faecal extracts from colorectal cancer patients and healthy controls |
|
https://doi.org/10.18632/oncotarget.26022
|
| 33278-33289 |
|
| Singlecell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel |
|
https://doi.org/10.18632/oncotarget.26044
|
| 33290-33301 |
|
| The vesicular transfer of CLIC1 from glioblastoma to microvascular endothelial cells requires TRPM7 |
|
https://doi.org/10.18632/oncotarget.26048
|
| 33302-33311 |
|
| Role of textural heterogeneity parameters in patient selection for 177LuPSMA therapy via response prediction |
|
https://doi.org/10.18632/oncotarget.26051
|
| 33312-33321 |
|
| A safety study of newly generated antipodoplaninneutralizing antibody in cynomolgus monkey <i>Macaca fascicularis</i> |
|
https://doi.org/10.18632/oncotarget.26055
|
| 33322-33336 |
|
| Intratumor heterogeneity of <I>HMCN1</I> mutant alleles associated with poor prognosis in patients with breast cancer |
|
https://doi.org/10.18632/oncotarget.26071
|
| 33337-33347 |
|
| Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triplenegative breast cancer subtype by transcriptome profiling |
|
https://doi.org/10.18632/oncotarget.26072
|
| 33348-33359 |
|
| Loss of Gadd45b accelerates BCRABLdriven CML |
|
https://doi.org/10.18632/oncotarget.26076
|
| 33360-33367 |
|
| <i>N</i>2´Hydroxyphenyl2propylpentanamide OHVPA a histone deacetylase inhibitor induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells |
|
https://doi.org/10.18632/oncotarget.26077
|
| 33368-33381 |
|
| Genetic disruption of calpain1 and calpain2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib |
|
https://doi.org/10.18632/oncotarget.26078
|
| 33382-33395 |
|
| Metaanalysis of the likelihood of FOXC2 expression in early and latestage tumors |
|
https://doi.org/10.18632/oncotarget.26087
|
| 33396-33402 |
Reviews
|
| Cancer stem cells in progression of colorectal cancer |
|
https://doi.org/10.18632/oncotarget.23607
|
| 33403-33415 |
|
| Inhibition of interleukin1 receptorassociated kinase 1 IRAK1 as a therapeutic strategy |
|
https://doi.org/10.18632/oncotarget.26058
|
| 33416-33439 |
Corrections
|
| Correction: Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer |
|
https://doi.org/10.18632/oncotarget.26113
|
| 33440-33440 |
|
| Correction: Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel |
|
https://doi.org/10.18632/oncotarget.26114
|
| 33441-33441 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
